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Abstract
Introduction
COVID-19 is an example of a newly emerging, infectious disease with pandemic potential. Although there 
are numerous studies on this disease, the main focus now is on relating COVID-19 with possible long-term 
sequelae, as well as neurological manifestations. The aim of this study is to investigate the relationship 
between SARS-CoV-2 infection and the development of new-onset seizures, that is, in patients who had 
not been previously diagnosed with epilepsy.
Methods
A systematic search of articles and preprints was performed in three databases (MedLine, Scopus and 
Web of Science) between February 24 and March 7, 2021. The MeSH terms and keywords used in the 
search were: (“SARS-CoV-2” OR “COVID-19”) AND (“Seizures” OR “Status Epilepticus” OR “Electroen-
cephalography” OR “EEG”) NOT (“Epilepsy”).
Results
Twenty-one studies were included 21 studies in the systematic review after screening. It was estimated 
that approximately 2.9 % of COVID-19 patients with neurological symptoms developed new-onset seizu-
res and about 0.67% of the total number of COVID-19 patients developed new-onset seizures. The most 
common coexisting symptoms among these patients were fever, vomiting, cough and malaise. Antiepi-
leptic treatment was key to the improvement of the health status of patients who developed new-onset 
seizures.
Conclusion
With the limited data available, it is currently impossible to establish a direct association between SARS-
CoV-2 infection and the development of new-onset seizures. The pathophysiologic mechanism causing 
the seizures cannot yet be determined either. However, it can be concluded that generally, these seizures 
are successfully reverted with antiepileptic treatment and patients usually respond favorably.
Keywords: COVID-19, SARS-CoV-2, neurological sequelae, seizures, status epilepticus.
1. Introduction
Infectious diseases are a global problem, especially 
due to the emergence of new potentially dangerous 
infectious agents (1). The betacoronavirus genus is 
an example of a family of emerging diseases with 
pandemic potential (2): severe acute respiratory sy-
ndrome (SARS-CoV) in 2002, Middle East respira-
tory syndrome (MERS-CoV) in 2012 (3,4), and the 
first SARS-CoV-2 cases in 2019 (5,6). SARS-CoV-2 
was declared a pandemic by the World Health Or-
ganization on March 11, 2020.
Articles analyzing the clinical features of the first 
SARS-CoV-2 outbreak reported a high incidence 
of rather nonspecific symptoms such as fever, cou-
gh, respiratory distress or diarrhea (7-9), with no 
mention of neurological manifestations. Neurologi-
cal manifestations were first evaluated by Mao et 
al. 2020(10), where they were estimated to appear 
in 36% of COVID-19 patients. The most common 
symptoms found were dizziness, headache, loss of 
taste and loss of smell. The first case of seizures as-
sociated with COVID-19 was also reported in this 
study. However, most later reviews reported diver-
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se neurological alterations (headache, dizziness or 
altered level of consciousness), with a much lower 
prevalence compared to respiratory complications 
(11,12). For this reason, neurological manifestations 
were reported later.
Regarding pathophysiology, the neuroinvasive 
pathway of SARS-CoV-2 is uncertain. Mainly, two 
hypothetical pathways have been suggested: neural 
dissemination (Figures 1 and 2) through the olfac-
tory nerve and the cribriform plate, a pathway pre-
viously demonstrated for MERS-CoV and SARS-
CoV in animals (13,14) and humans (15-17); and 
hematogenous dissemination (Figure 3) through 
cerebral circulation (18). Considering these possible 
pathways, neural invasion of SARS-CoV-2 may oc-
cur in a similar manner and be related to neurologi-
cal symptoms (11).
Although there is an increasing number of articles 
on long-term, neurological sequelae in patients with 
COVID-19, there is still not much evidence on this 
regard and more studies are still needed to estimate 
them. Therefore, we performed a systematic review 
of the current literature on the topic, focusing on a 
very specific neurological manifestation: new-onset 
seizures. The reported cases of seizures caused by 
COVID-19 are few and the incidence is low. Still, 
they should not be dismissed, since they have an 
effective treatment and early detection could be of 
great clinical importance (19).
Therefore, the aim of this systematic review is to 
study the relationship between SARS-CoV-2infec-
tion and the development of new-onset seizures in 
patients who had not been previously diagnosed 
with epilepsy. The possible etiology of this mani-
festation, its outcome and potential associated co-
morbidities are also investigated.
2. Methods
A systematic review of the literature on COVID-19 
and its neurological sequelae was performed. Spe-
cial focus is placed on seizures in patients who had 
not been previously diagnosed with epilepsy. The 
PRISMA statement for reporting systematic re-
views was followed as a guideline to develop this 
review (20).
2.1. Search strategy
A systematic search of articles and preprints was 
conducted in three databases (MedLine, Scopus and 
Web of Science) between February 24 and March 7, 
2021. The MeSH terms and keywords used when 
searching for articles on seizures as a sequela of 
COVID-19were: (“SARS-CoV-2” OR “COVID-19”) 
AND (“Seizures” OR “Status Epilepticus” OR “Elec-
troencephalography” OR “EEG”) NOT (“Epilepsy”).
2.2. Data management
The articles found after searching the databases 
were imported to Zotero (a free reference manager). 
After eliminating duplicates, the title and abstract 
of the remaining articles were read, eliminating 
those that were not related to the topic. The articles 
that were not relevant to the topic, those that did 
not mention seizures in patients with COVID-19 
and those that only focused on neurological seque-
lae in general were also dismissed. Once the articles 
were screened, the reading process began to select 
the definitive articles for this systematic review. 
The selection criteria were the following: 
1. Original studies, cohort studies, case and con-
trol studies or case series published in English 
that provided information about patients not 
diagnosed with epilepsy who developed seizu-
res in the context of COVID-19.
2. Articles that provided sufficient information 
about patients, neurological symptoms (espe-
cially seizures), tests performed (imaging and 
laboratory tests), treatments and patients’ pro-
gress.
3. Articles where the patients had tested positi-
ve for SARS-CoV-2 by any diagnostic method 
(PCR, serological tests or antigen test).
The exclusion criteria were:
1. Systematic or narrative reviews, meta-analyses 
or letters to the editor.
2. Studies that did not provide enough informa-
tion about patients or studies where the infor-
mation provided was not relevant for this re-
view.
The choice of including or excluding the remaining 
articles was made by two of the three authors to 
avoid selection, performance or attrition bias. Once 
the choice had been made, the results were shared 
and any discrepancies were solved through dialo-
gue. The selected articles were screened for other 
references that could provide original information 
about the topic of the study that may have been ac-
cidentally overlooked during the systematic search. 
The inclusion and exclusion criteria were applied 
to the relevant references. Figure 4 (PRISMA flow-
chart) summarizes the process described above.
Lastly, two of the authors performed a bias assess-
ment of all the observational studies included in 
the review using a modified version of the New-
castle-Ottawa Scale (NOS)to determine the quality 
of the studies. Discrepancies between the authors 
were solved through dialogue. As the NOS is not 
suitable for assessing case-control studies, these 
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were excluded from the assessment because, accor-
ding to the level of evidence of the JAMA network, 
these are the most biased (21).
3. Results
Of the 790 records identified, 21 studies were inclu-
ded in this systematic review, following the pro-
cedure described above. The selected articles are 
summarized in Tables 1, 2 and 3. Table 2 includes 
the values obtained on the modified NOS (22). The 
values were classified as unsatisfactory (0-3 points), 
satisfactory (4-5 points), good (6-7 points) and very 
good (8-9 points). Following these criteria, four ar-
ticles were rated as satisfactory, three as good and 
one as very good. The detailed assessment of bias 
for each article according to the modified NOS can 
be found in the appendix (Table 1).
Table 1 summarizes the information obtained (23-
35). Some of the most common symptoms among 
are fever, cough, vomiting and malaise. Most stu-
dies show that patients present comorbidities, al-
though we found some exceptions. For example, in 
a study by Farsano et al. (26), a patient without pre-
vious history developed a seizure with clonic move-
ments of the right arm. In another study by Suhail 
Hussain (31), a patient with hardly any symptoms 
experienced four episodes of generalized clonic-to-
nic seizures. Regarding the treatment, the efficacy 
of antiepileptic drugs is noteworthy. With the ex-
ception of four studies where patients worsened or 
even died (28, 30), studies showed that patients sto-
pped having seizures and their health status impro-
ved until they were eventually discharged.
Tables 2 and 3 summarize the cohort observational 
studies (36-42). Thanks to the sample size, it was 
possible to estimate the frequency of new-onset sei-
zures in COVID-19 patients by mathematical analy-
sis. Thus, it was estimated that approximately 2.9% 
of patients with neurological symptoms derived 
from COVID-19 will develop new-onset seizures. 
The total proportion of COVID-19 patients that will 
develop new-onset seizures was also estimated, as 
shown in Table 3. It was estimated that 0.67% of 
COVID-19 patients will suffer from new-onset sei-
zures. Table 2 explains the mathematical analysis 
performed.
4. Discussion
This systematic review estimated that less than one 
in ten patients with COVID-19 and neurological 
symptoms developed seizures, and that out of every 
10,000 COVID-19 patients, 67 developed new-onset 
seizures. These data indicate that although neurolo-
gical alterations are common among COVID-19 pa-
tients (43), this is not the case with seizures. In fact, 
paradoxically, these cases represent a relatively low 
proportion (between 1% and 26%) in contrast to 
other neurological manifestations (36, 38).
Patients that develop new-onset seizures associa-
ted with COVID-19 usually share a great number 
of comorbidities and suffer from severe COVID-19 
symptoms. However, despite the severity, most 
seizures revert successfully with antiepileptic drug 
treatment (44). In addition, as shown by Hepburn et 
al., 2020 (33), patients with clinical signs of seizures 
or unexplained encephalopathy can benefit from 
electroencephalographic monitoring in addition to 
empiric antiepileptic treatment.
There are different hypotheses for the appearance 
of these seizures. On one hand, they might be as-
sociated with the pathophysiologic characteristics 
of severe cases of COVID-19. These cases present 
hypoxic encephalopathy, cardiovascular events 
and hypercytokinemia, which might be responsi-
ble for triggering these seizures (45). On the other 
hand, seizures might be caused by invasion of the 
nervous system by the virus, as suggested in diffe-
rent studies in which was detected in the CSF of 
COVID-19 patients that subsequently developed 
encephalitis (46). Lastly, the appearance of seizures 
in COVID-19 patients might be nothing but a mere 
coincidence and a matter of chance. This is not sur-
prising considering the extremely low ratio of re-
ported COVID-19 cases with seizures and the total 
amount of reported COVID-19 cases (47). 
Regarding the strengths of this study, it is important 
to point out the adherence to the PRISMA system 
when elaborating this review. The exhaustive and 
comprehensive search carried out, the meticulous 
interpretation of all the studies included, as well 
as the assessment of potential bias are also worth 
highlighting. Moreover, the quality of the studies 
was determined using the NOS. Regarding the li-
mitations of this study, it is possible that the search 
equation used and the use of only three databases 
and may have led to relevant studies being over-
looked. The short follow-up time of observational 
studies may be another possible limitation of this 
study.
5. Conclusion
Although little is known about the sequelae of CO-
VID-19, this review presents different perspectives 
and estimates on the incidence rates of new-on-
set seizures in COVID-19 patients. About 2.9% of 
COVID-19 patients with neurological symptoms 
developed new-onset seizures and about 0.67% of 
the total number of COVID-19 patients developed 
new-onset seizures. However, with the limited data 
available, it is currently impossible to establish a 
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direct association between SARS-CoV-2 infection 
and the development of new-onset seizures. The 
pathophysiologic mechanism behind the seizures 
cannot yet be established, but it can be concluded 
that antiepileptic drug treatment can successfully 
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Figure 1. Simplified representation of the axonal transport machinery. On the left, a neuron is depicted with cuts in the soma 
membrane in some parts of the axonal growth cone. This represents the hypothetical axonal transport of the virus.
Figure 2. Neural dissemination. Presynaptic exocytosis and postsynaptic endocytosis of the virus are depicted.
Figure 3. Presence of coronavirus in astrocytes. Representation of an infected astrocyte and hematogenous dissemination.
FIGURES
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Figure 4. Flowchart following PRISMA guidelines (20).
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et al., 2020 (36) Cohorts n=40,469 1 month n=9086 (22.5%) n=258 (2.8%) 8
Brandon L. Waters 
et al., 2021 (37) Cohorts n=79 4 months n=6 (7.5%) n=3 (3.7%) 4
Ling Mao et 
al., 2020 (10) Cohorts n=214 1 month n=78 (36.5%) n=1 (1.3%) 7
Carlos Manuel 




Cohorts n=725 1 month n=119 (16.4%) n=10 (8.4%) 6
Stephane Kremer 
et al., 2020 (40) Cohorts n=190 1 month n=190 n=4 (2.1%) 7
Pranusha Pinna 
et al., 2020 (41) Cohorts n=650 2 months n=50 (7.7%) n=13 (26%) 4
Sara Radmard 
et al., 2020 (42) Cohorts n=33 3 weeks n=33 n=6 (18.2%) 4
Table 2. Summary of observational cohort studies that do not provide individualized patient information.
Author, date 




et al., 2020 (36) Cohorts n=40 469 1 month n=258 (0.64%)
Ling Mao et al., 2020 (10) Cohorts n=214 1 month n=1 (0.47%)
Carlos Manuel et 
al., 2020 (38) Cohorts n=841 1 month n=5 (0.60%)
Abdelkader Mahammedi
et al., 2020 (39) Cohorts n=725 1 month n=10 (1.38%)
Pranusha Pinna 
et al., 2020 (41) Cohorts n=650 2 months n=13 (2%)
Table 3. Total number of patients with COVID-19 and number of reported new-onset seizures.
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FIRST RESULT - TABLE 2 (% of COVID-19 patients with neurolo-
gical manifestations that develop new-onset seizures)
Author, date and reference Relative importance (total number of neurological manifestations)
(number of seizures/total 
number of neurological 
manifestations) × 100
Nalleballe et al., 2020 (36) 9086 2.8
Mao et al., 2020 (10) 78 1.3
Carlos Manuel et al., 2020 (38) 483 1
Mahammedi et al., 2020 (39) 119 8.4
Kremer et al., 2020 (40) 190 2.1
Pinna et al., 2020 (41) 50 26
Radmard et al., 2020 (42) 33 18.2
% of COVID-19 patients with neurological manifestations that developed new-onset seizures:
WEIGHTED ARITHMETIC MEAN 2.921047913
Observations Waters et al., 2021 is not included in this analysis since they do not report the total number of patients that developed neurological manifestations.
Appendix -  Table 2. Mathematical analysis carried out to obtain the results.
SECOND RESULT - TABLE 3 (% of COVID-19 patients that developed new-onset seizures)
Author, date and 
reference
Relative importance (total 
number of COVID-19 patients)
(number of seizures/ total number 
of COVID-19 patients) × 100
Nalleballe et al., 2020 (36) 40,469 0.64
Mao et al., 2020 (10) 214 0.47
Carlos Manuel et al., 2020 (38) 841 0.6
Mahammedi et al., 2020 (39) 725 1.38
Pinna et al., 2020 (41) 650 2
% of COVID-19 patients with neurological manifestations that developed new-onset seizures:
WEIGHTED ARITHMETIC MEAN: 0.6714804541
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